Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI chatbot aims to teach women heart attack symptoms

NCT ID NCT07416734

Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether an AI-powered app called HeartBot II can improve women's awareness of heart attack symptoms. About 200 women will be randomly assigned to use the app right away or wait 12 weeks. Participants complete surveys about their knowledge and confidence in recognizing a heart attack.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HeartBot II app (AI chatbot program)
What this could lead to
If it works, this could lead to a simple, scalable tool to help women recognize heart attack symptoms and seek emergency care faster.
What could go wrong
This is a small, early-stage study focused on awareness, not on actual health outcomes. The app may not change behavior or reduce heart attack deaths.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women * 25 years or older * Living in the US * University of California, San Francisco Health patient * Possessing a smartphone with a data plan or Wi-Fi access Exclusion Criteria: * Individuals who identify as male * Having self-reported cognitive impairment * Having history of heart disease or stroke * Healthcare professional/trainee * Working in the healthcare field

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Participants must be women aged 25 years or older are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease heart disorder stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Participants must be women aged 25 years or older Participants should have no self-reported history of heart disease or stroke Participants should have no terminal illness or diagnosed cognitive impairment, including Alzheimer's disease Participants should not be A healthcare professionals or healthcare trainees Participants should not be employed in the healthcare field Participants should possess A smartphone with an active data plan or access to wi-fi Participants should reside in the united states and be A university of california, san francisco health patient

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California, San Francisco

    San Francisco, California, 94143, United States